Sirolimus-based immunosuppressive regimens in organ transplantation have been associated with a lower than expected incidence of CMV disease. Whether sirolimus has a similar effect on CMV reactivation after allogeneic hematopoietic stem-cell transplantation (HSCT) is not known. 
Introduction
Cytomegalovirus (CMV) infection remains a challenging problem after allogeneic hematopoietic stem cell transplantation (HSCT) 1, 2 . CMV reactivation and disease was the leading cause of infectious morbidity and mortality in the 1970s and 1980s in HSCT recipients [3] [4] [5] [6] . The discovery and clinical use of the deoxyguanosine analogues acyclovir 7, 8 and ganciclovir 9, 10 for the prevention of CMV reactivation, and the implementation of preemptive ganciclovir treatment based on systematic CMV antigen 11 or nucleic acid monitoring 12 in peripheral blood, significantly decreased the impact of CMV infection after HSCT 1, 2, 13 by the late 1990s.
Valganciclovir has allowed the oral administration of effective doses of ganciclovir [14] [15] [16] , thus minimizing the additional risks associated with prolonged administration of intravenous medications and central catheter use. Although preemption has reduced unnecessary ganciclovir exposure and consequent toxicity, it is still limited by its associated myelosuppression and risk of secondary infections that affect those who require treatment at the time of CMV reactivation 1, 2, 13 .
The effect of CMV seropositivity of donor-recipient pairs, as well as that of acute graft-versushost disease (GVHD) and its treatment, on the risk of CMV reactivation and disease after HSCT is well-established 3, 4, [17] [18] [19] [20] . While the relative importance of different HSCT regimens on CMV infection, including non-myeloablative or reduced-intensity conditioning 21, 22 , T-cell depletion 23, 24 , and donor relatedness 20,25,26 is established, the effect of GVHD prophylaxis strategies other than T-cell depletion has not been well studied. A small cohort study 27 suggested that a mycophenolate-containing regimen may increase the cumulative incidence of CMV reactivation, but most studies have not had enough patients nor variability to study the contribution of GVHD prophylaxis regimens to the risk of CMV reactivation 1, 2 .
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Randomized trials of sirolimus-based immunosuppressive regimens in solid organ transplantation have observed decreased cumulative incidence of CMV disease in patients receiving sirolimus 28, 29 . We reported a reduced incidence of CMV reactivation in an initial experience with a combination of sirolimus and tacrolimus for GVHD prophylaxis 30 , although that trial was limited to matched-related HSCT recipients and the incidence of acute GVHD was low 31 . Thus, in the present study we sought to evaluate whether sirolimus exposure during early transplantation had an effect on CMV infection particularly compared to calcineurin inhibitors cyclosporine and tacrolimus, as well as other risk factors for early CMV reactivation in a recent cohort of adult HSCT recipients at our institution. Six-hundred-sixty procedures were performed during the study period. Six umbilical cord blood HSCT procedures were excluded. There were 18 patients who underwent two or more transplant procedures: only their first transplant was included in this analysis, such that 21 HSCT procedures were excluded, and their survival was censored at the time of the second transplant.
Patients and methods

Patients
Three patients with missing data on donor CMV serologic status were excluded. Twenty-four patients were excluded because they did not undergo blood CMV DNA testing during the study period, the primary outcome of interest, mostly because of early death after HSCT. Thus a final
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From cohort of 606 patients undergoing an initial HSCT during the study period was used for the present study.
Covariates and definitions
Data on covariates of interest were identified through the DFCI/BWH HSCT database, the Partners Healthcare System Research Patient Data Repository, and through review of the electronic and paper medical records. Covariates included age at the time of HSCT, sex, race, primary disease that necessitated HSCT, date of transplant, donor and recipient CMV IgG antibody status, BMT disease risk group, HLA-matching between donor and recipient, relatedness of donor (sibling or not), mode in which stem cells were obtained ( .
All modes of T-cell depletion (CD8-38 or CD6-depletion 39 , CD34+ selection) used during the For personal use only. on October 24, 2017. by guest www.bloodjournal.org From study period were analyzed as a single group given the few patients who underwent a specific Tcell manipulation procedure. Methotrexate, cyclosporine, tacrolimus, mycophenolate mofetil, and prednisone were included individually in the analysis, but as patients who received sirolimus always received concomitant tacrolimus for initial GVHD prophylaxis during the study period, one variable was created to consider both of these medications together, and one variable was created that considered the effects of tacrolimus in the absence of sirolimus. With the exception of methotrexate, individual GVHD prophylaxis drugs were started during conditioning, tapered starting between day +60 and day +100, and discontinued by day +180 unless GVHD occurred.
Given this exposure pattern, individual drugs were modeled as baseline risks in this analysis.
Overall acute GVHD severity was coded as grade 0-I versus grades II-IV because the latter received systemic treatment with corticosteroids and other immunosuppressants, which are known to increase CMV reactivation 1, 2, 13 , and to allow comparability with previous studies, which have consistently used this dichotomization. Time to acute GVHD was defined as the time between transplantation (day 0) and diagnosis of GVHD. Donor and Recipient CMV serology was coded as a 4-level covariate (D-/R-, D-/R+, D+/R-, D+/R+) 3, 18 . Given the relatively few HSCT recipients belonging to each of several non-White races, these were analyzed as a group.
As the cumulative incidence of CMV reactivation was noted to have decreased steadily over the study period, a 4-level transplant period covariate was created to account for potential unmeasured covariates and secular trends of CMV reactivation.
CMV testing and preemptive treatment
Whole blood CMV DNA testing utilizing a hybrid capture assay (Digene Corporation, Gaithersburg, MD) 40,41 for monitoring of CMV reactivation at DFCI/BWH started in April 2000
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From and was used consistently throughout the study period. Patients were tested once or twice a week after engraftment, while hospitalized for any reason, and on every clinic visit after discharge and beyond day +100 after HSCT. Clinic visits usually took place every week to every two weeks, depending on the time after transplant, intercurrent problems and immune reconstitution. Patients with a positive CMV hybrid capture result were treated at the discretion of their transplant oncologist, who decided whether to start preemptive treatment immediately or wait for a repeat positive result for confirmation. Patients usually received preemptive IV ganciclovir 5mg/Kg twice daily, oral ganciclovir 1000mg thrice daily, or valganciclovir 900mg twice daily (adjusted for renal function as needed) for 10 to 14 days, or until CMV testing became negative, followed by a 2-4 week suppression period.
All patients received acyclovir prophylaxis (400mg orally or 200mg IV three times daily) beginning with conditioning until a year after HSCT, or longer if they remained on immunosuppression for GVHD; no patient received prophylactic ganciclovir or valganciclovir.
Red cell and platelet support was provided with irradiated, leukocyte-reduced products obtained locally or through the American Red Cross during the study period. All platelets transfused were single-donor apheresis products. Leukocyte-reduced products were considered CMV-free by the hospital blood bank and administered to all HSCT patients (including CMV D-/R-recipients) independent of the blood donor's CMV status. A patient's first positive CMV hybrid capture result, independent of the CMV DNA concentration, was considered an event for the purpose of this analysis 40 
Statistical analysis
Initial univariate exploration of the baseline covariates was performed using two-sided Fisher's exact test or Wilcoxon tests. We generated univariate Kaplan-Meier survival curves of time to CMV reactivation for all baseline covariates; log-rank was used to test for equality over strata. In addition, CMV reactivation cumulative probability plots were generated for covariates of particular interest. 
RESULTS
CMV reactivation in the cohort during first 100 days after HSCT
A total of 5,016 CMV DNA hybrid capture assays (CMV-HCA) were performed during the first 100 days after HSCT in the cohort with a median of 8 assays per patient (interquartile range
[IQR] 6-10, range 1-21). An initial positive CMV-HCA was detected in 225 patients (37.1%) a median of 39 days after HSCT (IQR, 27-52; range, 2-100 days). These events occurred over 45,064 patient-days at-risk of CMV reactivation through day +100, for an overall incidence rate of 0.50 cases/100 patient-days (95% CI, 0.44-0.57). The cumulative incidence and crude incidence rates of CMV reactivation during this period were similar among patients of different age, sex, underlying disease, and BMT disease risk group (Table 1) . When stratified by the 4 possible categories of CMV donor/recipient serostatus pairs, there was a discrete and significant gradation in the incidence of CMV detection after HSCT. Patients who were CMV D-/R+ had 
Sirolimus exposure in the cohort and its distribution among known risk factors for CMV reactivation
The distribution of sirolimus-tacrolimus use for GVHD prophylaxis was explored in order to identify possible confounding among covariates that were associated with CMV reactivation (Table 2 ).
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Age, sex, BMT disease risk groups, and conditioning regimens were similar among patients prescribed sirolimus-based GVHD prophylaxis and those who received other regimens. The distribution of disease groups that necessitated HSCT was different among patients who received sirolimus-tacrolimus, with higher proportions of patients with CML and NHL, but lower proportion of patients undergoing HSCT for AML. However, none of these baseline covariates was associated with an increased incidence proportion of CMV reactivation.
Interestingly, the distribution of sirolimus-tacrolimus use in the cohort was higher among some covariates associated with decreased risk of CMV reactivation, but also with others associated with increased risk of CMV reactivation. The sirolimus-tacrolimus group had lower incident acute GVHD grades II-IV when compared with the rest of the cohort (26.6% v. 36.4%, p=0.01).
The proportion of non-White recipients was lower (4.4% v. On the other hand, more sirolimus-tacrolimus recipients were CMV D+ and/or R+ (64.3% v.
55.9%, p=0.04) and more of them received hematopoietic stem cells from unrelated donors (60.3% v. 46.0%, p=0.0005). Both covariates were associated with increased cumulative incidence of CMV reactivation in the cohort. Physicians were unaware of any relationship between sirolimus use and CMV infection during the study period.
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Multivariate model of CMV reactivation
Univariate Cox models for time to a first positive CMV-HCA were computed for covariates found to be associated with CMV reactivation in the cohort (Table 3 CMV reactivation stratified by stem cell source confirmed a small but relatively higher hazard of CMV reactivation early after HSCT in patients receiving PBSC, with crossing of the hazard curves at day +20, with a subsequent persistently lower hazard of CMV reactivation for the rest of the initial 100 days after HSCT. As the primary objective of the study was to analyze the contribution of GHVD prophylaxis regimens to the risk of CMV reactivation after HSCT, the final multivariate model was stratified by stem cell source and is presented in Table 3 .
In the multivariable adjusted model, only donor-recipient CMV serostatus pairs, incident acute grade II-IV GVHD (adjusted HR 1.52, 95% CI 1.09-2.12, p=0.01) and sirolimus-tacrolimus use for GVHD prophylaxis (adjusted HR 0.46, 95% CI 0.27-0.78, p=0.004) remained significant predictors of CMV reactivation at a p<0.05 significance level. In addition, methotrexate use for GVHD prophylaxis became a significant risk of CMV reactivation in the adjusted model (adjusted HR 1.74, 95% CI 1.07-2.83, p=0.02). The adjusted risk of PBSC on CMV reactivation cannot be directly calculated as this covariate was stratified in this analysis. The gradation of the findings of the multivariable model, the effect of CMV serostatus pairs and sirolimus-tacrolimus prophylaxis on the cumulative probability of CMV reactivation is seen in Figures 2A and 2B .
The effect of sirolimus-tacrolimus prophylaxis and incident acute GVHD grades II-IV on the cumulative probability of CMV reactivation is presented in Figure 2C . There was no interaction (effect modification) between acute GVHD and sirolimus-tacrolimus use in the model on the adjusted HR of CMV reactivation (p=0.67).
Sensitivity analysis
One interesting feature of the data is that 45 (18.3%) CMV D-/R-patients had at least one positive CMV-HCA result. Although the cumulative probability of CMV reactivation in D-/Rrecipients is similar to previous reports 3, 20 , it is higher than recent cohorts in which the prevention of transfusion-associated CMV was minimized with use of leukoreduction by There were 87 patients with persistent CMV viremia during the first 100 days after HSCT for a cumulative incidence of 14.4% and an overall incidence rate of 0.166 cases/100 patient-days post HSCT (95% CI 0.134-0.204). The multivariate analysis of risk of persistent CMV-HCA positivity is presented in Table 4 using the same model covariates as in the main analysis. Given that only 3 patients had persistent CMV-HCA in the CMV D-/R-group, the crude and adjusted HR for the other CMV D/R strata are quite larger than in the main analysis. The adjusted HR for incident acute GVHD grades II-IV was 1.87 (95% CI 1.23-3.11, p=0.016) and that for use of sirolimus-tacrolimus for GVHD prophylaxis was 0.22 (95% CI 0.09-0.55, p=0.001) using cyclosporine as reference group. In this stringent model, reduced-intensity conditioning became significantly protective with an adjusted HR of 0.40 (95% CI 0.17-0.94, p=0.036) whereas methotrexate use did not maintain its significance as a risk factor. Removing patients with CMV D-/R-serostatus and using patients with CMV D+/R-serostatus as the reference group provided similar adjusted HR estimates (data not shown).
The effect of CMV serostatus pairs and sirolimus-tacrolimus prophylaxis on the cumulative probability of persistent CMV reactivation is presented graphically in Figures 3A and 3B . The effect of sirolimus-tacrolimus prophylaxis and incident acute GVHD grades II-IV on the cumulative probability of persistent CMV reactivation is presented in Figure 3C .
CMV disease during the first year after HSCT
There were 8 cases of CMV disease during the first year of follow up after HSCT for a cumulative incidence of 1.32%. Four cases were diagnosed before day +100; three of them had Two patients who received sirolimus-tacrolimus GVHD prophylaxis developed CMV disease for a cumulative incidence of 0.79% while the remainder of patients were not on this regimen (cumulative incidence 1.69%, p=0.47).
Cohort Survival
The one-year survival for the cohort was 58.6% (95% CI, 56.6-60.7). To explore the impact of CMV serostatus and sirolimus-tacrolimus use for GVHD prophylaxis on survival at one year, the cohort was divided into four possible strata according to CMV serostatus (D-/R-versus any 18 and use of sirolimus-tacrolimus prophylaxis for GVHD. Among patients who did not receive sirolimus-tacrolimus prophylaxis, the crude one-year survival was 57.6% (95% CI 
Discussion
In this study of a large recent cohort of HSCT recipients, CMV serostatus of donor-recipient pairs and incident grade II-IV acute GVHD remain the most significant and stable predictors of CMV reactivation [1] [2] [3] [4] [5] 17, 20, 45 , verifying the main observations by Meyers and colleagues twenty years after their landmark study 3 . In contrast to the available management in the 1980's, the overall cumulative incidence of CMV disease was 0.66% at day +100 and 1.32% at one year after HSCT.
During the period studied, HSCT patients received a variety of treatments that included the evaluation and incorporation into practice of different conditioning strategies, stem cell sources, and GVHD prophylaxis regimens. This variability allowed us to study and model the adjusted contribution of several potential risk factors of CMV reactivation after HSCT.
In multivariable models that adjusted for CMV donor-recipient serostatus pairs, incident acute GVHD, race, conditioning regimens, HLA-matching, donor relatedness, transplant period, other GVHD prophylaxis drugs, and stratified by stem cell source, we demonstrated a significant reduction in the incidence of CMV reactivation associated with a GVHD prophylaxis regimen As sirolimus was consistently given with tacrolimus during the study period, we cannot address whether the protective effect observed on the risk of CMV reactivation is due to sirolimus alone or to the combination of sirolimus and tacrolimus. Tacrolimus was frequently used in the cohort during the study period, and although its adjusted HR for risk of CMV reactivation was 0.66 when compared to cyclosporine as reference group for initial or persistent CMV viremia, it did not reach statistical significance in either model (p=0.14 and 0.35, respectively).
The measured protective effect of sirolimus-based GVHD prophylaxis observed is probably a conservative estimate as false-positive CMV-HCAs likely occured 42 , thus attenuating the observed association. All GVHD prophylaxis regimens were modeled as baseline exposures in the present study, which may have further attenuated the observed sirolimus-tacrolimus
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From protective association for patients in whom sirolimus was subsequently discontinued due to adverse effects 47 , concern for drug interactions 48 , or withdrawal of immunosuppression to increase graft-versus-leukemia effect in cases of relapsed disease. Furthermore, whether the observed association is maintained beyond day +100 was not studied, given the further investment needed for capturing sirolimus exposure later in the transplant process when GVHD prophylaxis is systematically tapered. Of note, the observed decreased risk of CMV reactivation was additional and adjusted to the lower incidence of acute grade II-IV GVHD observed in the cohort among sirolimus-tacrolimus recipients (Tables 3-4 and Figures 2-3 ). We did not study the effect of sirolimus on CMV reactivation and disease when it was administered as a second drug in patients who developed acute or chronic GVHD. Whether sirolimus-containing regimens provide protection against CMV infection when initiated for the treatment of acute or chronic GVHD remains to be determined.
Sirolimus inhibits the kinetics of CMV replication in experimentally infected human foreskin fibroblasts through binding to rictor complex (mammalian target of rapamycin kinase complex 2), which is modified in CMV-infected cells 49 . Yet the effect of sirolimus in this in vitro system only delays and decreases the peak levels of CMV titers during productive infection 49, 50 and it is not likely to explain the clinical effect on CMV infection observed in the cohort. In HSCT, reactivation of CMV latent in recipient tissues early after transplantation is the predominant phenomenon that leads to detectable viremia and clinical disease 2, 51 . The potential effect of sirolimus on the mechanisms of CMV desilencing and reactivation at the cellular level have not been studied 51 , but could perhaps be due to enhanced inhibition of rictor-mediated blockade as suggested in the productive infection models 49 , but more likely due to effects on other mechanisms such as histone modifications 52 or chromatin remodeling 53 of epigenetic CMV . Methotrexate use had an increased adjusted HR of CMV reactivation in the main model, but it did not remain significant in the stringent model of persistent CMV positivity, whereas reduced-intensity conditioning became significantly protective for CMV reactivation in the stringent model.
The role of PBSC on the risk of CMV reactivation deserves mention. Although the overall risk of CMV reactivation was lower among patients who received PBSC, its adjusted HR could not be addressed in the multivariate models due to crossing hazards, but was controlled for by stem cell source stratification in the multivariable analysis. The initial increased risk when compared to bone marrow transplant is likely due to earlier engraftment observed with PBSC that allows detection of CMV reactivation earlier when using assays that depend on leukocyte counts such as the CMV-HCA. The overall decreased risk and decreased hazard after day +20 is likely due to earlier immune reconstitution that has been observed when using PBSCs for HSCT 54,56 .
The observed association on the decreased risk of CMV reactivation with a sirolimus-tacrolimus GVHD prophylaxis regimen when patients are exposed early after HSCT is robust. Confirmation of this finding from data on CMV reactivation of randomized GVHD prophylaxis trials currently 
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